Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 5, 2025 • 6:00 PM ET

Date/Time Source News Release
12/12/2024 08:15 AM EST Business Wire Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
11/19/2024 07:17 AM EST GlobeNewswire Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
11/14/2024 04:36 PM EST PR Newswire Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
11/14/2024 07:15 AM EST GlobeNewswire Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
11/08/2024 08:30 AM EST Business Wire Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
11/07/2024 08:30 AM EST Business Wire Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
11/06/2024 05:55 PM EST GlobeNewswire Appili Therapeutics Announces Results of Special Meeting of Shareholders
11/06/2024 08:30 AM EST Business Wire Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
11/06/2024 08:00 AM EST PR Newswire Evofem Secures Investor Support for Proposed Merger through Voting Agreements
10/31/2024 08:30 AM EDT Business Wire Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
Page